SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alivus Life Sciences - Quaterly Results

15 May 2025 Evaluate
The March 2025 quarter revenue stood at Rs. 6495.45 millions, up 21.05% as compared to Rs. 5365.97 millions during the corresponding quarter last year.The company has announced a 44.86% increase in its profits to Rs . 1418.68  millions for the  quarter ended March 2025 compared to Rs. 979.37 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 2085.20 millions compared to 1445.77 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 6495.45 5365.97 21.05 23868.84 22832.14 4.54 23868.84 22832.14 4.54
Other Income 100.88 31.31 222.20 345.70 120.42 187.08 345.70 120.42 187.08
PBIDT 2085.20 1445.77 44.23 7171.54 6862.88 4.50 7171.54 6862.88 4.50
Interest 12.60 3.64 246.15 24.14 15.46 56.14 24.14 15.46 56.14
PBDT 2072.60 1442.13 43.72 7147.40 6847.42 4.38 7147.40 6847.42 4.38
Depreciation 159.70 145.34 9.88 606.09 534.52 13.39 606.09 534.52 13.39
PBT 1912.90 1296.79 47.51 6541.31 6312.90 3.62 6541.31 6312.90 3.62
TAX 494.22 317.42 55.70 1685.04 1604.02 5.05 1685.04 1604.02 5.05
Deferred Tax 15.45 6.88 124.56 60.64 81.88 -25.94 60.64 81.88 -25.94
PAT 1418.68 979.37 44.86 4856.27 4708.88 3.13 4856.27 4708.88 3.13
Equity 245.07 245.05 0.01 245.07 245.05 0.01 245.07 245.05 0.01
PBIDTM(%) 32.10 26.94 19.15 30.05 30.06 -0.04 30.05 30.06 -0.04

Alivus Life Sciences Share Price

1050.35 -10.40 (-0.98%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×